BCRX

BioCryst Pharmaceuticals, Inc. Press Releases

$10.18
*  
0.50
4.68%
Get BCRX Alerts
*Delayed - data as of Jan. 30, 2015  -  Find a broker to begin trading BCRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema
1/26/2015 6:58:00 AM - GlobeNewswire


BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
1/14/2015 7:05:00 AM - GlobeNewswire


BioCryst to Present at J.P. Morgan Healthcare Conference
1/6/2015 6:50:00 AM - GlobeNewswire


BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer
1/5/2015 7:05:00 AM - GlobeNewswire


BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
12/23/2014 5:50:00 PM - GlobeNewswire


BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection
12/23/2014 6:15:00 AM - GlobeNewswire


BioCryst''s RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza
12/22/2014 3:55:00 AM - GlobeNewswire


BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema
12/18/2014 7:07:00 AM - GlobeNewswire


BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema
12/18/2014 7:07:00 AM - GlobeNewswire


BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses
12/15/2014 7:15:00 AM - GlobeNewswire


BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses
12/15/2014 7:15:00 AM - GlobeNewswire


BioCryst to Present at Two Upcoming Investor Conferences
11/20/2014 7:10:00 AM - GlobeNewswire


BioCryst Reports Third Quarter 2014 Financial Results
11/6/2014 6:47:00 AM - GlobeNewswire